FDA official tells firms "be conscious of vulnerabilities"

A lesson for companies in the wake of the heparin adulteration which occurred last year is that vulnerabilities can and should be monitored, Deborah Autor, director of compliance in the US FDA's drug centre, told attendees at the recent DCAT meeting in New York.